Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomihisa Niitsu

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Annals of General Psychiatry|June 25, 2010
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophreniaAkihiro Shiina, Yukihiko Shirayama, Tomihisa Niitsu, et al.
Acta Neuropsychiatrica|October 30, 2015
Increased serum levels of serine enantiomers in patients with depressionKenji Hashimoto, Taisuke Yoshida, Masatomo Ishikawa, et al.
Psychiatry Research|March 9, 2022
Ifenprodil tartrate treatment of adolescents with post-traumatic stress disorder: A double-blind, placebo-controlled trialTsuyoshi Sasaki, Kenji Hashimoto, Tomihisa Niitsu, et al.
Psychiatry and Clinical Neurosciences|November 29, 2016
Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disordersJunko Matsumoto, Yoshiyuki Hirano, Kenji Hashimoto, et al.
Journal of Psychiatric Research|April 18, 2021
Oxytocin system dysfunction in patients with treatment-resistant schizophrenia: Alterations of blood oxytocin levels and effect of a genetic variant of OXTRYusuke Nakata, Nobuhisa Kanahara, Atsushi Kimura, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 21, 2011
Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophreniaTomihisa Niitsu, Yukihiko Shirayama, Daisuke Matsuzawa, et al.
Neuropsychopharmacology Reports|February 6, 2020
Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophreniaNoriko Kudo, Hidenaga Yamamori, Tamaki Ishima, et al.
The International Journal of Neuropsychopharmacology|March 13, 2018
Plasma Levels of Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) Are Associated with Hippocampal Volume and Cognitive Performance in Patients with SchizophreniaNoriko Kudo, Hidenaga Yamamori, Tamaki Ishima, et al.
Psychiatry Research|July 15, 2015
Decreased levels of serum oxytocin in pediatric patients with Attention Deficit/Hyperactivity DisorderTsuyoshi Sasaki, Kenji Hashimoto, Yasunori Oda, et al.
PCN Reports : Psychiatry and Clinical Neurosciences|June 13, 2024
Association between precautionary behaviors against coronavirus disease and psychosocial factors in outpatients with a pre-existing disease and their attendantsKeita Idemoto, Tomihisa Niitsu, Akihiro Shiina, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Annals of General Psychiatry|June 25, 2010
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophreniaAkihiro Shiina, Yukihiko Shirayama, Tomihisa Niitsu, et al.
Acta Neuropsychiatrica|October 30, 2015
Increased serum levels of serine enantiomers in patients with depressionKenji Hashimoto, Taisuke Yoshida, Masatomo Ishikawa, et al.
Psychiatry Research|March 9, 2022
Ifenprodil tartrate treatment of adolescents with post-traumatic stress disorder: A double-blind, placebo-controlled trialTsuyoshi Sasaki, Kenji Hashimoto, Tomihisa Niitsu, et al.
Psychiatry and Clinical Neurosciences|November 29, 2016
Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disordersJunko Matsumoto, Yoshiyuki Hirano, Kenji Hashimoto, et al.
Journal of Psychiatric Research|April 18, 2021
Oxytocin system dysfunction in patients with treatment-resistant schizophrenia: Alterations of blood oxytocin levels and effect of a genetic variant of OXTRYusuke Nakata, Nobuhisa Kanahara, Atsushi Kimura, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 21, 2011
Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophreniaTomihisa Niitsu, Yukihiko Shirayama, Daisuke Matsuzawa, et al.
Neuropsychopharmacology Reports|February 6, 2020
Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophreniaNoriko Kudo, Hidenaga Yamamori, Tamaki Ishima, et al.
The International Journal of Neuropsychopharmacology|March 13, 2018
Plasma Levels of Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) Are Associated with Hippocampal Volume and Cognitive Performance in Patients with SchizophreniaNoriko Kudo, Hidenaga Yamamori, Tamaki Ishima, et al.
Psychiatry Research|July 15, 2015
Decreased levels of serum oxytocin in pediatric patients with Attention Deficit/Hyperactivity DisorderTsuyoshi Sasaki, Kenji Hashimoto, Yasunori Oda, et al.
PCN Reports : Psychiatry and Clinical Neurosciences|June 13, 2024
Association between precautionary behaviors against coronavirus disease and psychosocial factors in outpatients with a pre-existing disease and their attendantsKeita Idemoto, Tomihisa Niitsu, Akihiro Shiina, et al.
Pageof 7